Tricor, Procetofen, LF-178, Lipanthyl, Normalip, Secalip; Fenofibrate; LF 178, LF178,Controlip, durafenat
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mM * 1 mL in DMSO |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
Fenofibrate 具有相当程度的抑制 CYP2B6 (IC50=0.7±0.2 μM) 和 CYP2C19 (IC50=0.2±0.1 μM) 的效力。根据参考文献[1]，非诺贝特对CYP2C8（IC50=4.8±1.7 μM）和CYP2C9（IC50=9.7 μM）具有中等抑制作用。与 PPARα 相比，非诺贝特对细胞色素 P450 环氧化酶 (CYP)2C 具有更大的亲和力并对其进行抑制。非诺贝特是一种众所周知的 PPARα 激动剂，但根据对 209 种常用药物和相关异生素的体外评估，它似乎也是细胞色素 P450 环氧化酶 (CYP)2C 的强抑制剂。与 PPARα (EC50=30 μM) 相比，非诺贝特对 CYP2C 的亲和力 (EC50=2.39±0.4 μM) 大于 10 倍。低剂量的非诺贝特会降低 CYP2C8 活性而不激活 PPARα[2]。
|
||
|---|---|---|---|
| 体内研究 (In Vivo) |
在 10 μg/g/天的适度剂量下，非诺贝特每天可分别抑制 CYP2C8 过度表达诱导的视网膜和脉络膜新生血管形成 29% (P=0.021) 和 36% (P=1.2×10−9)。 2]。
|
||
| 动物实验 |
|
||
| 参考文献 |
[1]. Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78(3):639-48.
[2]. Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964(16)30448-0 |
| 分子式 |
C20H21CLO4
|
|
|---|---|---|
| 分子量 |
360.83
|
|
| CAS号 |
49562-28-9
|
|
| 相关CAS号 |
Fenofibrate (Standard);49562-28-9;Fenofibrate;49562-28-9;Fenofibrate-d6;1092484-56-4;Fenofibrate-d4;1092484-57-5
|
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1[H])C(C1C([H])=C([H])C(=C([H])C=1[H])OC(C(=O)OC([H])(C([H])([H])[H])C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=O
|
|
| InChi Key |
YMTINGFKWWXKFG-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
|
|
| 化学名 |
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
|
|
| 别名 |
|
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外) |
|
|||
|---|---|---|---|---|
| 溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.93 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 33.33 mg/mL (92.37 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7714 mL | 13.8569 mL | 27.7139 mL | |
| 5 mM | 0.5543 mL | 2.7714 mL | 5.5428 mL | |
| 10 mM | 0.2771 mL | 1.3857 mL | 2.7714 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06191133 | Not yet recruiting | Drug: Fenofibrate Procedure: Cervical Conization |
Cervical Intraepithelial Neoplasia Invasive Cervical Cancer |
Lindsay Ferguson, MD | August 1, 2024 | Phase 1 |
| NCT05514119 | Recruiting | Drug: Fenofibrate | Liver Transplant | Mayo Clinic | August 17, 2022 | Phase 2 |
| NCT05883865 | Recruiting | Drug: Larotrectinib Sulfate Procedure: Bone Scan |
Recurrent Glioma Refractory Glioma |
National Cancer Institute (NCI) |
August 23, 2017 | Phase 2 |
| 444 | Completed | Drug: Tricor (fenofibrate), 145 mg, film-coated tablet |
Hypertriglyceridemia Metabolic Syndrome |
First People's Hospital of Hangzhou | June 1, 2022 |
|
Clofibric Acid
Rosiglitazone
Alpinetin
Oroxin A
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
NMR
粤公网安备 44011102003439号